Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sysmex ( (JP:6869) ) has provided an update.
Sysmex reported a 1.7% decline in net sales to ¥500.0 billion for the year ended March 31, 2026, with operating profit dropping 40.8% and profit attributable to owners falling 33.9%, reflecting margin pressure and weaker profitability despite only modest top-line slippage. Profitability ratios also deteriorated, as return on equity fell to 7.3% and operating margin to 10.4%, although total assets and equity attributable to owners increased, lifting the equity ratio to 71.4%.
Despite the earnings contraction, cash flow from operating activities remained solid at ¥73.8 billion and the company raised its annual dividend from ¥32.00 to ¥38.00 per share, including commemorative payments tied to the 30th anniversary of its listing. Sysmex signaled confidence by forecasting a recovery in fiscal 2027, guiding for 7.0% sales growth and a rebound in operating profit, while maintaining an active shareholder return policy as its balance sheet continues to strengthen.
The most recent analyst rating on (JP:6869) stock is a Hold with a Yen1500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.
More about Sysmex
Sysmex Corporation is a Japan-based medical device company specializing in clinical laboratory testing systems and related diagnostic reagents. Listed on the Tokyo Stock Exchange, it focuses on in-vitro diagnostics, particularly hematology and other laboratory solutions for hospitals and healthcare providers worldwide, positioning itself as a key player in the global diagnostics market.
Average Trading Volume: 4,389,826
Technical Sentiment Signal: Sell
Current Market Cap: Yen812.6B
Find detailed analytics on 6869 stock on TipRanks’ Stock Analysis page.